Drugs / ZIMISTOBART
ZIMISTOBART
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04349267 | Jul 2020 → Aug 2024 | neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06094296 | Nov 2023 → Aug 2024 | non-small cell lung carcinoma | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZIMISTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068467 ↗ |
| Known as | Anti-NKG2A mAb | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068467 ↗ |
| Known as | BMS-986315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04349267 ↗ |
| Known as | BMS-986315-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068467 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068467 ↗ |